TABLE 1.

Ciprofloxacin-nonsusceptible S. pneumoniae isolates: serotypes, susceptibility to quinolones, resistance determinants, PFGE types, and MLST characteristics

Isolatea	Serotype	MIC (μg/ml)b			Amino acid substitutionsc				Efflux pumpd	PFGE type	MLST allelic profilee	ST	Other isolation
		CIP	LVX	MOX	GyrA	GyrB	ParC	ParE
WR-1/99	3	4	1	0.5	WT	WT	D83N K137N	WT	+	A	NP
ML-2/02	3	4	1	0.12	WT	WT	WT	WT	ND	B	NP
SU-1/98	6A	4	0.5	0.12	WT	WT	S79F	I460V	−	C	7-13-9-1-10-1-45	1363	New ST
SZ-1/98	6B	4	0.5	0.12	WT	WT	S79F	WT	+	D	8-13-14-4-1-4-14	200	Denmark, Taiwan
BY-8/01	6B	4	2	0.25	WT	WT	K137N	WT	+	E	7-25-4-2-48-20-28	497	Finland
BY-4/00	7C	4	0.5	0.12	WT	WT	WT	WT	+	F	NP
BY-5/00	7C	4	0.5	0.12	WT	WT	D83G	WT	−	F	NP
BY-2/98	7F	≥32	8	2	S81F	WT	D83N K137N	WT	−	G1	8-9-2-1-6-1-17	191	United Kingdom Denmark, Norway, Finland, The Netherlands, Uruguay, Brazil
BY-3/99	7F	≥32	8	2	S81F	WT	D83N K137N	WT	−	G2	8-9-2-1-6-1-17	191
SA-1/99	9V	4	2	0.25	WT	WT	K137N	WT	+	H1	7-11-10-1-6-8-1	156	Spain9V-3
BY-9/01	9V	4	2	0.25	WT	WT	D83N K137N	WT	−	H2	7-11-10-1-6-8-1	156
SU-3/01	10A	4	2	0.25	WT	WT	S79F	I460V	+	J	NP
SU-4/02	10A	4	1	0.25	WT	WT	S79F	I460V	+	J	NP
SU-6/02	11A	4	1	0.12	WT	WT	D83G	WT	+	K	NP
SA-2/02	14	4	1	0.12	WT	WT	K137N	WT	+	L	7-5-10-18-6-145-1	1477	New ST
BY-1/98	15A	4	0.5	0.12	WT	WT	S79F	WT	+	M	8-10-2-16-7-26-1	410	United Kingdom
Wpl-1/99	18C	4	0.5	0.12	WT	WT	S79Y	I460V	+	N	NP
Wpl-2/99	18C	4	0.5	0.12	WT	WT	S79F	I460V	−	N	NP
BY-10/02	19A	4	2	0.25	WT	WT	WT	I460V	+	O	18-5-9-1-47-1-6	482	Finland
SU-5/02	19A	4	0.5	0.12	WT	WT	WT	WT	+	P	2-19-2-17-6-22-14	276	The Netherlands
BY-6/01	19F	4	1	0.25	WT	WT	WT	I460V	+	Q1	1-5-4-12-5-3-8	423	United Kingdom
ML-1/01	19F	8	1	0.25	WT	WT	S79F	I460V	+	Q2	1-5-4-12-5-3-8	423
KO-1/99	22F	4	0.5	0.12	WT	WT	S79F	I460V	−	R	NP
LO-1/99	23B	4	0.5	0.12	WT	WT	WT	I460V	+	S	NP
PR-1/99	23F	4	0.5	0.12	WT	WT	S79F	WT	−	T	7-5-1-1-13-31-14	440	United Kingdom
KR-1/99	23F	4	0.5	0.12	WT	WT	K137N	WT	+	U	7-8-8-18-10-6-14	1364	New ST
WR-2/00	23F	4	0.5	0.12	WT	WT	S79F K137N	WT	−	V	4-4-2-4-4-1-1	81	Spain23F−1
Wpr-1/01	23F	4	2	0.25	WT	WT	WT	WT	+	W	15-17-4-16-6-19-17	239	United Kingdom
BY-7/01	23F	4	1	0.12	WT	WT	S52G K137N	WT	+	X	2-10-1-43-6-31-6	1014	New ST
SU-2/01	35F	4	1	0.12	WT	WT	WT	P454S I460V	−	Y	NP
GD-1/01	37	4	1	0.12	WT	WT	WT	WT	ND	Z	NP

^aAn isolate name contains an abbreviation of the center (BY, Bydgoszcz; GD, Gdańsk; KO, Kołobrzeg; KR, Kraków; LO, Łódź; ML, Mława; PR, Przemyśl; SA, Sanok; SU, Suwałki; SZ, Szczecin; Wpl, Warsaw 1; Wpr, Warsaw 2; WR, Wrocław), the sequential number of a resistant isolate from a given center, and the two last digits of the isolation year.

^bCIP, ciprofloxacin; LVX, levofloxacin; MOX, moxifloxacin; WT, wild-type.

^cAmino acid substitutions involved in resistance are shown in boldface type.

^dND, not determinable.

^eNP, analysis not performed.